LONDON (MarketWatch) -- Myriad Genetics Inc. said its Phase 2 trial of Flurizan did not achieve statistical significance in patients with mild to moderate Alzheimer's disease. Myriad said the drug did ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
This is a preview. Log in through your library . Abstract This paper presents a Bayesian significance test for stationarity of a regression equation using the highest posterior density credible set.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback